Related Experiment Video

Updated: Aug 10, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

Fundamental considerations of beta-adrenoceptor subtypes in human heart failure

Peter Molenaar1, William A Parsonage

  • 1Discipline of Medicine, The University of Queensland, The Prince Charles Hospital Chermside, Queensland 4032, Australia. p.molennar@mailbox.uq.edu.au

Trends in Pharmacological Sciences
|June 7, 2005
PubMed

Insights

Beta-blockers improve heart failure management, but questions persist about beta2-adrenoceptor roles and genetic variations. Research explores receptor subtypes and paradoxical benefits in heart failure treatment.

Area of Science:

  • Pharmacology and Cardiovascular Medicine
  • Molecular and Cellular Biology
  • Genetics and Personalized Medicine

Background:

  • Beta-adrenoceptor antagonists are crucial in treating human heart failure.
  • Uncertainty exists regarding the specific roles of beta2-adrenoceptors in heart failure.
  • Genetic variations in beta1- and beta2-adrenoceptors may influence treatment outcomes.

Purpose of the Study:

  • To address fundamental questions regarding beta-adrenoceptor antagonist use in heart failure.
  • To investigate the clinical significance of blocking beta2-adrenoceptors in addition to beta1-adrenoceptors.
  • To reconcile paradoxical findings from animal models with current clinical applications.

Main Methods:

  • Review and synthesis of existing evidence on beta-adrenoceptor function in heart failure.
  • Discussion of polymorphic receptor variants and their impact on therapeutic response.
  • Analysis of studies on low-affinity beta1-adrenoceptors, beta3-adrenoceptors, and receptor system normalization.

Main Results:

  • Debate continues on the incremental benefit of combined beta1/beta2-adrenoceptor blockade.
  • Adrenoceptor polymorphisms are implicated in variable patient responses to beta-blockers.
  • Evidence suggests potential roles for low-affinity beta1- and ventricular beta3-adrenoceptors.

Conclusions:

  • The precise role of beta2-adrenoceptors in heart failure requires further elucidation.
  • Understanding receptor polymorphisms may lead to personalized heart failure therapies.
  • Reconciling animal model findings with clinical practice is essential for advancing heart failure treatment.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...